[go: up one dir, main page]

MX2010001429A - Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco. - Google Patents

Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco.

Info

Publication number
MX2010001429A
MX2010001429A MX2010001429A MX2010001429A MX2010001429A MX 2010001429 A MX2010001429 A MX 2010001429A MX 2010001429 A MX2010001429 A MX 2010001429A MX 2010001429 A MX2010001429 A MX 2010001429A MX 2010001429 A MX2010001429 A MX 2010001429A
Authority
MX
Mexico
Prior art keywords
ascorbic acid
reducing
nasal delivery
powdered medicament
induced toxicity
Prior art date
Application number
MX2010001429A
Other languages
English (en)
Inventor
Peter Lambert
Merkus W H M Franciscus
Original Assignee
Britannia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Ltd filed Critical Britannia Pharmaceuticals Ltd
Publication of MX2010001429A publication Critical patent/MX2010001429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe el uso de ácido arcórbico en la elaboración de un medicamento en polvo para distribución nasal para aliviar la toxicidad, el medicamento comprende un agente activo tal como apomorfina que exhibe toxicidad a tejido ciliado.
MX2010001429A 2007-08-06 2008-08-04 Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco. MX2010001429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0715285.3A GB0715285D0 (en) 2007-08-06 2007-08-06 Improvements in or relating to powdered medicaments for nasal delivery
PCT/GB2008/002648 WO2009019463A1 (en) 2007-08-06 2008-08-04 Powdered medicament for nasal delivery of ascorbic acid for reducing apomorphine induced toxicity to ciliated tissue

Publications (1)

Publication Number Publication Date
MX2010001429A true MX2010001429A (es) 2010-06-23

Family

ID=38529367

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001429A MX2010001429A (es) 2007-08-06 2008-08-04 Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco.

Country Status (14)

Country Link
US (1) US20110086875A1 (es)
EP (1) EP2187881A1 (es)
JP (1) JP2010535750A (es)
KR (1) KR20100044881A (es)
CN (1) CN101820874B (es)
AU (1) AU2008285473A1 (es)
BR (1) BRPI0815088A2 (es)
CA (1) CA2707292A1 (es)
EA (1) EA201070251A1 (es)
GB (1) GB0715285D0 (es)
MX (1) MX2010001429A (es)
NZ (1) NZ583767A (es)
WO (1) WO2009019463A1 (es)
ZA (1) ZA201001600B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43042A (fr) 2015-09-28 2018-08-08 Ever Neuro Pharma Gmbh Composition aqueuse d'apomorphine pour une administration sous-cutanée
KR20250023394A (ko) 2022-06-15 2025-02-18 에버 뉴로 파르마 게엠베하 아포모르핀 전구약물 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI81258C (fi) * 1982-02-01 1990-10-10 Sandoz Ag Foerfarande foer framstaellning av en farmaceutisk komposition foer nasal administration.
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
BE1007402A5 (nl) * 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US5944012A (en) * 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP4754067B2 (ja) * 1997-12-02 2011-08-24 アルキメデス ディヴェロプメント リミテッド 鼻孔投与用組成物
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US6251599B1 (en) * 1998-11-06 2001-06-26 Selective Genetics, Inc. Stabilized nucleic acid compositions and methods of preparation and use thereof
EP2130554B1 (en) * 1999-02-22 2012-09-05 University of Connecticut Albumin-free factor VIII formulations
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
ATE522211T1 (de) * 2000-09-20 2011-09-15 Jagotec Ag Stabilisierte fibrat-mikropartikel
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials

Also Published As

Publication number Publication date
GB0715285D0 (en) 2007-09-12
AU2008285473A1 (en) 2009-02-12
EA201070251A1 (ru) 2010-08-30
WO2009019463A1 (en) 2009-02-12
CN101820874B (zh) 2012-12-26
JP2010535750A (ja) 2010-11-25
US20110086875A1 (en) 2011-04-14
ZA201001600B (en) 2012-08-29
KR20100044881A (ko) 2010-04-30
BRPI0815088A2 (pt) 2015-02-03
CN101820874A (zh) 2010-09-01
CA2707292A1 (en) 2009-02-12
NZ583767A (en) 2012-06-29
EP2187881A1 (en) 2010-05-26

Similar Documents

Publication Publication Date Title
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MX2010009336A (es) Composiciones farmaceuticas acuosas que contienen complejos de borato-poliol.
IN2012DN01233A (es)
MY167918A (en) Composition for use in the sublingual delivery of medicaments to humans
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
ZA200907355B (en) Titration of tapentadol
MX357820B (es) Composiciones para uso en la manufactura de medicamentos para tratamiento de esclerosis multiple progresiva.
MY159865A (en) Aqueous insulin preparations containing methionine
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
PH12012501630A1 (en) Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
TN2012000059A1 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
PH12015502593A1 (en) COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF THREE OR MORE ACTIVE AGENTS
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
MX2015004362A (es) Derivados de ketamina.
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
TW200738627A (en) Trialkylsilyl-indoles
MX2009011900A (es) Curacion de herida diabetica.
MX2010001429A (es) Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco.
ZA201404068B (en) The use of silver(i) complexes as active pharmaceutical ingredients (api's) iincluding anticancer agents
MX2012004087A (es) Sulfonamidas para la prevencion de diabetes.
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну

Legal Events

Date Code Title Description
FG Grant or registration